<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To investigate the major steps of thrombogenesis and to identify the differences in these steps between idiopathic patient group and control group </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Fibrinogenesis was studied by measuring the activated factor VII, total and free levels of tissue factor pathway inhibitor (TFPI) </plain></SENT>
<SENT sid="2" pm="."><plain>The fibrinolysis step was investigated by determining the global fibrinolytic capacity </plain></SENT>
<SENT sid="3" pm="."><plain>The endothelial function was assessed by measuring the levels of soluble <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules, namely soluble intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (sICAM-1), soluble vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (sVCAM-1) and soluble E-selectin molecule </plain></SENT>
<SENT sid="4" pm="."><plain>The exclusion criteria from "idiopathic" patient group were abdominal surgery, pregnancy, use of oral contraceptives, anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome, <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>The congenital factors like mutations of factor-V Leiden and prothrombin, deficiencies of proteins C and S, antithrombin, <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> and <z:hpo ids='HP_0011899'>hyperfibrinogenemia</z:hpo> were ruled out </plain></SENT>
<SENT sid="6" pm="."><plain>The total number of patients was reduced from 96 to 9 (7 with portal vein <z:mp ids='MP_0005048'>thrombosis</z:mp>, 2 <z:hpo ids='HP_0002639'>Budd Chiari syndrome</z:hpo>) by exclusion criteria </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The levels of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules sICAM-1, sVCAM-1, free TFPI levels and global fibrinolytic capacity were significantly different (P&lt;0.05) in the patient group indicating an <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and a lower fibrinolytic activity </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: These results show that this patient group should be tested by means of <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and managed differently </plain></SENT>
</text></document>